Skip to main content
Bildspel: 

Moberg Pharma’s Interim report for July - September 2019 to be published on November 19 - Invitation to teleconference

STOCKHOLM, November 12th, 2019 - On November 19th, 2019, at 08:00 am (CET), Moberg Pharma AB (OMX: MOB) will present its Interim report for July - September 2019. Investors, analysts and journalists are hereby invited to participate in a teleconference at 3:00 pm (CET) on the same date.

The teleconference will be hosted by Moberg Pharmas’s CEO Anna Ljung and VP Finance Mark Beveridge. The presentation will be held in English.

Date:             November 19th, 2019
Time:             3:00 pm (CET)

To participate in the conference, please dial in on any number below before the start of the call:

SE:                +46 8 566 427 04
US:                +1 833 526 83 98

The quarterly report and other information material will be made public on:
http://www.mobergpharma.com/investors/calendarpresentations

For additional information, please contact:
Anna Ljung, CEO, Phone: + 46 70 766 60 30, e-post: anna.ljung@mobergpharma.se
Mark Beveridge, VP Finance, Phone: + 46 76 805 82 88, e-post: mark.beveridge@mobergpharma.se

About Moberg Pharma, www.mobergpharma.com
Moberg Pharma AB (publ) is a Swedish pharmaceutical company focused on commercializing proprietary innovations based on drug delivery of proven compounds. The company’s main asset, MOB-015, is a novel topical treatment for onychomycosis, for which phase 3 data in more than 800 patients is expected in late 2019 in North America and the first half of 2020 in Europe. The pipeline also includes the late-stage asset BUPI for pain relief in oral mucositis. Clinical data generated for both assets indicate they have the potential to become market leaders in their respective niches. Moberg Pharma is headquartered in Stockholm and the company’s shares are listed on the Small Cap list of the NASDAQ OMX Nordic Exchange Stockholm (OMX: MOB).